CCT2 played a pivotal role in clinical tubulin-binding agent-resistant or CCT2-overexpressing cancers, and targeting the β-tubulin/CCT2 complex might provide these cancers with a novel chemotherapeutic strategy (Lin et al., 2009). This evidence concerns the gene CCT2 and cancer.